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Background: Pancreatic cancer (PC) is considered the most lethal cancer and approximately 10% of PC is
hereditary. The purpose of the study was to assess attitudes of at-risk family members with two or more relatives
affected with pancreas cancer (PC) toward PC risk and future screening options.
Methods: At-risk family members and primary care controls were surveyed regarding perceived PC risk, PC
worry/concern, attitude toward cancer screening, screening test accuracy, and intentions regarding PC screening
via blood testing or more invasive endoscopic ultrasound (EUS).
Results: PC family members reported greater perceived risk of PC than controls (54% vs. 6%, respectively,
p< 0.0001). PC family members also reported higher levels of PC worry/concern than controls (p< 0.0001),
although 19% of PC family members indicated they were “not at all concerned” about getting PC. PC family
members indicated greater acceptance of a false-negative result on a PC screening test relative to controls (12% vs.
8%, p = 0.02). Both groups reported high (>89%) receptivity to the potential PC screening options presented,
though receptivity was greater among PC family members as compared to controls (p< 0.0001) for EUS. In
multivariable analyses, degree of PC concern (p< 0.0001) was associated with intention to screen for PC by blood
test and EUS, while perceived PC risk was associated with likelihood of undergoing EUS only (p< 0.0001).
Conclusions: Receptivity to screening options for PC appears high. Clinicians should address behavioral and
genetic risk factors for PC and foster appropriate concern regarding PC risk among at-risk individuals.
Keywords: Pancreatic cancer, Health behavior, Perceived risk, Screening intentionsIntroduction
Pancreatic cancer (PC) is the fourth leading cause of
cancer death among men and women in the U.S. [1].
The incidence rates of PC have increased by 1.5% per
year since 2004, and in 2012, it is estimated that there
will be 43,920 new cases of PC and 37,390 deaths due to
this disease [1]. The lifetime risk of PC is about 1 in 71
for males and females [1]. For all stages combined, the
5-year relative survival rate is 6% with survival at earlier
stages being 22% [1]. The causes of this deadly disease
are not well understood, but approximately 10% of* Correspondence: radeckibreitkopf.carmen@mayo.edu
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distribution, and reproduction in any mediumpancreatic cancer is hereditary [2], and a person’s chance
of developing this cancer increases two- to three-fold if
a first-degree relative (parent, sibling or child) has PC
[3]. Presently, the United States Preventive Services Task
Force (USPSTF) recommends against routine screening
for PC in the general population because of the low
prevalence of this malignancy, the limited accuracy and
invasiveness of the currently available tests, and the poor
outcomes of treatment [4]. However, screening at-risk
individuals is receiving increasing support [5-8] with a
recommended threshold to offer screening to those who
carry a ≥10-fold increased risk [9].
Recent advances in screening technology via serum or
stool tests or endoscopic ultrasound (EUS) hold promise
for detecting early-stage PC [10-15]. A blood or stoold Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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EUS because of lower invasiveness and cost, however,
biomarkers for PC are elusive and the efficacy of emer-
ging potential serum or stool panels remains unknown
with regard to early detection. The ability of EUS to as-
sist in diagnosing pancreatic malignancies has also been
demonstrated [16-19]. However, concerns with EUS re-
late to its invasive nature, cost, accuracy and availability
[16]. At the present time, blood and stool tests and EUS
remain areas of research as potential screening tools for
PC. Studies are underway to provide a stronger rationale
for their use among appropriate groups at particular risk
for developing PC [20,21], including a recent report
addressing the psychological impact of PC surveillance
among at-risk participants in a Dutch PC surveillance
study [22]. This study, which included only at-risk indi-
viduals who already agreed to surveillance, demonstrated
that surveillance was not associated with increased can-
cer worry or elevated anxiety or depression levels [22].
Understanding the perceptions of at-risk, unaffected PC
family members who are not enrolled in surveillance
regarding future screening options is important and
comparing their perceptions to individuals not at par-
ticular risk of PC would fill an existing gap in the
literature.
The objective of this study was to evaluate perceived
PC risk, PC worry and concern, and receptivity to future
PC screening options among at-risk unaffected family
members of individuals with PC relative to individuals
(controls) who more closely resemble the PC risk profile
for the general population. Individuals with a family his-
tory of cancer may overestimate their personal cancer
risk and report increased cancer-related worry or con-
cern; these factors may in turn positively or negatively
influence attitudes and behaviors toward screening
among this higher-risk group [23-28]. Furthermore, this
study sought to identify factors related to interest in
screening for PC and to assess expectations surrounding
the accuracy of PC screening tests.
Materials and methods
Study population and study procedures
All study procedures were approved by the Mayo Clinic
Institutional Review Board and all subjects provided
written informed consent to participate. Study subjects
were at-risk unaffected family members enrolled in the
Mayo Clinic Pancreatic Cancer Family Study, a study
conducted as part of the Specialized Program of Re-
search Excellence (SPORE) and Pancreatic Cancer Gen-
etic Epidemiology Consortium studies [3,29] as well as
primary care controls. At-risk family members included
those with two or more first- or second-degree relatives
affected with pancreatic adenocarcinoma. Control sub-
jects included those attending Mayo Clinic for a generalmedical exam. Relatives of individuals with PC and con-
trols comprising the comparison group for this study
were recruited from 4/27/2004 -1/24/2008. All partici-
pants completed a survey addressing perceived PC risk,
degree of PC worry/concern, attitude toward cancer
screening in general, and intentions regarding uptake of
PC screening if it were available as a blood test or endo-
scopic ultrasound (EUS).
Measures
Demographic and medical history data were collected
using a self-report survey instrument. The instrument
included items assessing age, sex, race/ethnicity, educa-
tion, smoking status (current, ever, never), household in-
come, and number of family members affected by
cancer.
Perceived risk of PC was assessed in absolute and
comparative terms [30]. Specifically, the item “How
likely do you think it is that you will get pancreatic can-
cer sometime in your life?” was used to assess absolute
perceived risk. Response options on a 5-point scale ran-
ged from “very likely” to “very unlikely.” Responses were
grouped for analysis to reflect “likely” (including the
responses “very likely” and “likely”) and “unlikely” (in-
cluding the responses “no feeling or opinion,” “unlikely,”
and “very unlikely”). Comparative risk perception was
assessed by the item: “Compared to most people of your
same age, sex, and race, what do you think your chances
are of getting pancreatic cancer sometime in your life?”
Response options included (1) “much higher” chance to
(5) “much lower” chance.
Pancreatic cancer worry and concern was assessed by
four items adapted from Lerman and colleagues [31].
Three items referred to the time period “during the past
month” and queried: “How often have you thought
about your chances of getting pancreatic cancer?” “How
often have thoughts about your chances of getting pan-
creatic cancer affected your mood?” and “How often
have thoughts about your chances of getting pancreatic
cancer affected your ability to perform your daily activ-
ities?” Response options included “not at all or rarely,”
“sometimes,” “often,” and “a lot”. A fourth item queried:
“How concerned are you about getting pancreatic can-
cer?” to which participants responded using a 4-point
Likert-type scale ranging from (1) “extremely concerned”
to (4) “not at all concerned”. Cronbach’s alpha for these
items was 0.78, demonstrating acceptable internal
consistency. For multivariable analysis, responses were
categorized as “concerned” (“extremely”/“moderately”)
or “not concerned” (“mildly”/“not at all”) for ease of
interpretation.
Participants’ willingness to take part in PC screening if
it were a blood test or EUS was assessed by two items,
using a four-point Likert response format with responses






n (%) n (%)
Sex 0.0004
Male 512 (49) 138 (38)
Female 533 (51) 223 (62)
Age (y) <0.0001
Mean (±SD) 65.6 (10.7) 53.7 (14.6)
<30 5 (0.5) 23 (6)
30-49 91 (9) 117 (32)
50-64 329 (31) 131 (36)
65-79 557 (53) 79 (22)
80+ 63 (6) 11 (3)
Current Smoker <0.0001
Yes 35 (3) 41 (11)
No 1002 (97) 320 (89)
Ever Smoker 0.17
Yes 468 (45) 178 (49)
No 569 (55) 183 (51)
Education 0.06
High school or less 317 (31) 91 (25)
Greater than high school 722 (69) 269 (75)
Household income ($) 0.71
Less than 20,000 91 (5) 23 (6)
20,000- 35,000 128 (13) 44 (13)
>35,000- 50,000 164 (17) 52 (15)
>50,000- 75,000 204 (21) 70 (21)
>75,000 415 (44) 151 (45)
Proportion of FDR with
any cancer, % (range)
12 (0–100) 17 (0–100) <0.0001
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tions read, “If a blood test were available to screen for
pancreatic cancer, how likely is it that you would take
it?” and “If a test were available to screen for pancreatic
cancer that required an upper endoscopic examination
(you would be sedated, or made drowsy, and a flexible
tube would be inserted through your mouth into your
stomach), how likely is it that you would take it?”
As data are not yet available regarding actual false-
negative or false-positive rates for PC screening tests
and the concepts themselves can be difficult to under-
stand [32], expectations surrounding the accuracy of a
PC screening test were assessed more generally. The fol-
lowing three items were presented: “It would be OK if a
test detects less than 100% of people who have pancreatic
cancer,” “If a test says I do NOT have pancreatic cancer
when I really DO, that is OK with me,” (false-negative)
and “If a test says I may have pancreatic cancer when I
really do NOT, that is OK with me” (false-positive). A
fourth item addressed cancer screening more generally:
“It would be OK if a test says cancer may be present in a
person who really does NOT have cancer.” These four
items were assessed using a “strongly agree” to “strongly
disagree” rating scale with a “do not know” option.
Statistical analysis
Data were descriptively summarized using frequencies
and percentages for categorical variables, and means and
standard deviations for continuous variables. Compari-
sons between group (PC family members or controls)
and psychosocial characteristics, likelihood to undergo
screening, and expectations of screening accuracy were
evaluated using multivariable logistic regression adjust-
ing for sex, age, smoking, and family history (first degree
relatives) of any cancer; odds ratios and 95% confidence
intervals (CI) are presented. Because multiple members
from the same family could participate in the PC family
member group, analyses were also conducted which
accounted for possible non-independence using general-
ized estimating equation (GEE) methodology. Family-
specific correlations for screening via blood test and
EUS were modeled using an exchangeable covariance
matrix. All statistical analyses were performed using SAS
9.2 (SAS Institute Inc., Cary, NC).
Results
Sample characteristics
A total of 378 PC family members and 1528 controls
consented and were sent a survey; 361 (96%) PC family
members (representing 115 different families) and 1045
(68%) controls completed the survey. Mean ages in the
two groups were 53.7 (±14.6) and 65.6 (±10.7) years, re-
spectively (p< 0.001). Relative to controls, PC family
members were younger, more likely to be female, currentsmokers, and have more first degree relatives with any
cancer (Table 1).
Perceived pancreatic cancer risk
A majority (54%) of PC family members reported that
they were likely to get PC in their lifetime relative to 6%
of controls (p< 0.0001). A similar pattern was observed
for comparative risk estimates, i.e., perceptions of risk
relative to most people of the same age, sex, and race,
with a majority (67%) of PC family members reporting a
greater risk vs. 5% of controls (p< 0.0001) (Table 2).
Pancreatic cancer related worry/concern
PC family members reported more frequent thoughts in
the past month about getting PC (47% vs. 5%, respect-
ively, p< 0.0001), with these thoughts affecting mood.
Overall, 81% of PC family members reported some de-
gree of concern (“extreme,” “moderate,” or “mild”) about







(n = 361) N (%)
P
PSYCHOSOCIAL CHARACTERISTICS
Chances of getting PC
sometime in life
compared to most
people of the same
age, race and sex
<0.00011
Much higher 14 (1) 130 (37)
Higher 40 (4) 108 (30)
About the same 461 (46) 93 (26)
Lower 186 (18) 7 (2)





Likely 61 (6) 193 (54)
Not likely 953 (94) 163 (46)
Frequency of thoughts
about chances of getting
PC during past month
<0.00012
Not at all or rarely 975 (95) 190 (53)
Sometimes 42 (4) 120 (34)
Often 3 (<1) 30 (8)
A lot 2 (<1) 18 (5)
Frequency of thoughts
about chances of getting
PC affecting mood during
the past month
<0.00012
Not at all or rarely 1004 (99) 294 (83)
Sometimes 13 (1) 48 (14)
Often 0 (0) 7 (2)
A lot 1 (<1) 6 (2)
Frequency of thoughts
about chances of getting
PC affecting ability to
perform daily activities
during the past month
0.0012
Not at all or rarely 1008 (99) 340 (96)
Sometimes 10 (1) 12 (3)
Often 0 (0) 1 (<1)
A lot 0 (0) 3 (<1)
Degree of concern about
getting PC
<0.00013
Extremely Concerned 16 (2) 37 (10)
Moderately Concerned 65 (6) 109 (31)
Mildly Concerned 334 (33) 143 (40)
Not at all concerned 607 (59) 68 (19)
Table 2 Psychosocial Characteristics and Outcome
Variables by Group (Continued)
OUTCOME VARIABLES
Likelihood of undergoing
PC screening if it were a
blood test
0.084
Extremely Likely 452 (44) 224 (63)
Likely 465 (45) 113 (32)
Unlikely 81 (8) 19 (5)
Extremely Unlikely 25 (2) 1 (<1)
Likelihood of undergoing
PC screening if it were
EUS
<0.00014
Extremely Likely 163 (16) 145 (41)
Likely 390 (39) 121 (34)
Unlikely 342 (34) 78 (22)
Extremely Unlikely 116 (11) 12 (3)
1 P-value obtained from combining “Much higher” and “Higher” versus “About
the same”, “Lower”, and “Much lower”.
2 P-value obtained from combining “Sometimes”, “Often”, “A lot” versus “Not
at all or rarely”.
3 P-value obtained from combining “Extremely Concerned”, “Moderately
Concerned” and “Mildly Concerned” versus “Not at all concerned”.
4 P-value obtained from combining “Extremely Likely” and “Likely” versus
“Unlikely” or “Extremely Unlikely”.
Radecki Breitkopf et al. Hereditary Cancer in Clinical Practice 2012, 10:8 Page 4 of 9
http://www.hccpjournal.com/content/10/1/8getting PC relative to 41% of controls, (p< 0.0001)
(Table 2).
Expectations surrounding screening test accuracy
A majority (>75%) of both PC family members and con-
trols expressed acceptance of a PC screening test that was
not 100% accurate (Table 3). PC family members indi-
cated greater acceptance of a false-negative result on a PC
screening test relative to controls (12% vs. 8%, p = 0.002).
Acceptance rates for false-positive test results were
slightly higher overall than acceptance rates for false-
negatives; however no differences were observed between
the two groups with regard to acceptance of false-positive
results both for a cancer screening test in general, and a
screening test for PC (both p> 0.05; Table 3).
Likelihood of undergoing PC screening
Overall, 89% of controls and 95% of PC family members
reported that they were “likely” or “extremely likely” to
undergo PC screening via a blood test (p = 0.08). Al-
though these rates were comparatively lower for PC
screening via EUS, (55% of controls and 75% of PC fam-
ily members), likelihood of uptake was higher in the PC
family member group relative to controls (p< 0.0001).
Those who were “likely” vs. “not likely” to undergo PC
screening via a blood test differed by group (PC family
member vs. control) (p = 0.007), age (p = .001), perceived
PC risk (p< 0.0001), and degree of cancer worry/con-
cern (p< 0.0001) in univariable analyses (Table 4). In a






(n = 361) N (%)
P-value1
Global View
It would be OK if a test
detects less than 100%
of people who have
pancreatic cancer.
0.27
Strongly Agree 401 (40) 133 (38)
Somewhat Agree 360 (36) 143 (41)
Somewhat Disagree 74 (7) 33 (9)
Strongly Disagree 90 (9) 18 (5)
Do not know 80 (8) 21 (6)
It would be OK if a test
says cancer may be
present in a person
who really does NOT
have cancer. (“false-positive”)
0.37
Strongly Agree 81 (8) 27 (8)
Somewhat Agree 206 (20) 80 (22)
Somewhat Disagree 217 (22) 75 (21)
Strongly Disagree 437 (43) 161 (45)
Do not know 67 (7) 15 (4)
Personal View
If a test says I do NOT
have pancreatic cancer
when I really DO, that is
OK with me. (“false-negative”)
0.02
Strongly Agree 34 (3) 17 (5)
Somewhat Agree 47 (5) 25 (7)
Somewhat Disagree 112 (11) 57 (16)
Strongly Disagree 762 (76) 251 (70)
Do not know 53 (5) 7 (2)
If a test says I may have
pancreatic cancer when
I really do NOT, that is
OK with me. (“false-positive”)
0.08
Strongly Agree 64 (6) 25 (7)
Somewhat Agree 146 (14) 63 (18)
Somewhat Disagree 219 (22) 77 (22)
Strongly Disagree 510 (51) 181 (51)
Do not know 71 (7) 12 (3)
1 P-value obtained from combining “Strongly Agree” and “Somewhat Agree”
versus “Somewhat Disagree” and “Strongly Disagree”. “Do not know”
responses were excluded.
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screening for PC via a blood test was associated with
greater degree of cancer worry/concern (p< 0.0001).
Group, age, and perceived PC risk were no longer inde-
pendently associated with screening likelihood by blood
test.Similar analyses were conducted with regard to the
likelihood of undergoing screening via EUS. In univari-
able analyses, likelihood of screening via EUS was asso-
ciated with the same factors as screening via a blood
test: group (p< 0.0001), age (p = 0.002), perceived PC
risk (p< 0.0001), and degree of cancer worry/concern
(p< 0.0001) (Table 5). In the multivariable context, only
perceived PC risk (p< 0.0001) and degree of cancer
worry/concern (p< 0.0001) remained significant. Ana-
lyses accounting for the possibility that data are corre-
lated within a family did not appreciably change results
in any of the models (results not shown).
Discussion
Comprehensive efforts are underway to better under-
stand the etiology of PC, to improve treatment out-
comes, and to develop and evaluate effective screening
technologies [8,33]. Receptivity toward potential future
screening options for pancreatic cancer among those at
significant risk is an important, yet understudied area.
Overall, receptivity toward screening was higher among
PC family members relative to controls; of the potential
screening options studied, receptivity was greater for the
less invasive method (blood test vs. EUS). These findings
are consistent with qualitative data reported by Lewis
[34] and are important with regard to developing early
detection methods that will be acceptable to the indivi-
duals for whom they are intended. Previous studies in-
cluding highly-selected, at-risk individuals have reported
actual uptake of PC screening ranging between 61% (for
EUS) and 67% (for MRI), which reflects variation in indi-
vidual preferences and provides evidence that uptake
cannot always be assumed [6,8]. Moreover, this study
established that individuals who have family members
with PC may exhibit greater worry and concern about
PC, perceive greater PC risk for themselves and that
these psychological responses are independent, positive
predictors of intention to undergo screening for PC via
blood test (worry/concern) and EUS (worry/concern and
perceived risk) were such screening tests to become
available in the future.
These findings are consistent with theoretical models
of voluntary health behavior that include the construct
of perceived vulnerability, such as protection motivation
theory [35] and the health belief model [36,37]. Specific-
ally, these models posit that willingness to undergo inva-
sive procedures would be less likely for an average risk
group of individuals, while those with heightened risk
perception, greater perceived susceptibility or vulnerabil-
ity and increased awareness of the severity of the target
disease, would express greater likelihood of undergoing
even an invasive screening test such as EUS. In this
investigation, it was these psychological constructs
that were predictive of likelihood of screening in the
Table 4 Intention to Screen for Pancreatic Cancer (PC): Blood Test Univariable and Multivariable Models
Univariable Multivariable
Not Likely N (%) Likely N (%) p-value Odds ratio (95% CI) p-value
N 126 1254
Group 0.007 0.7 (0.4, 1.3) 0.25
Control 106 (84) 917 (73)
PC Family member 20 (16) 337 (27)
Sex 0.31 1.3 (0.9, 2.0) 0.17
Male 53 (42) 587 (47)
Female 73 (56) 667 (53)
Age (y), mean± SD 66.2 ±13.4 62.1 ±12.8 0.001 0.98 (0.97, 1.00) 0.07
Likelihood of getting PC sometime in your life <0.0001 2.5 (0.9, 6.9) 0.08
Likely 6 (5) 247 (20)
Not likely 118 (95) 985 (80)
Degree of concern about getting PC <0.0001 5.0 (3.0, 8.5) <0.0001
Concerned 20 (16) 682 (55)
Not concerned 105 (84) 566 (45)
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at-risk individuals (PC family members) who fail to
recognize their vulnerability may be no more likely than
average-risk individuals (controls) to undergo screening.
This point underscores the importance of understanding
the nature of risk perception and concern in cancer
screening and the importance of allowing such percep-
tions to appropriately drive screening behavior. It also
underscores the importance of appropriate education on
risk to family members. In this study, individuals who
perceived themselves as likely to get PC in their lifetimeTable 5 Intention to Screen for Pancreatic Cancer (PC): Endos
Models








Age (y), mean± SD 63.8 ± 12.4
Likelihood of getting PC sometime in your life
Likely 36 (7)
Not likely 505 (93)
Degree of concern about getting PC
Concerned 192 (35)
Not concerned 354 (65)were over three times as likely as those who did not hold
this perception to be willing to undergo EUS screening,
irrespective of group status. Thus, there is a great need
to measure and understand the complexities of these
constructs more fully in future research on PC, perhaps
using multi-dimensional measures of risk beliefs such as
the one developed by Hay and colleagues [38,39].
In this study, PC family members perceived their risk
of developing PC during their lifetime as greater com-
pared to others of their same age, sex, and race. They
also reported significantly higher levels of PC-relatedcopic Ultrasound (EUS) Univariable and Multivariable
Univariable Multivariable
Likely N (%) p-value Odds ratio (95% CI) p-value
819
<0.0001 1.2 (0.9, 1.7) 0.30
553 (68)
266 (32)
0.82 1.1 (0.9, 1.4) 0.46
379 (46)
440 (54)
61.6 ± 13.2 0.002 1.002 (0.99, 1.01) 0.63
<0.0001 3.4 (2.2, 5.3) <0.0001
214 (27)
589 (73)
<0.0001 2.1 (1.6, 2.6) <0.0001
502 (62)
313 (38)
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with the literature on perceived risk and concern among
those at increased risk of cancer due to family history.
However, previous studies have focused primarily on
breast, colorectal, and lung cancer [32,40-42]. PC is dif-
ferent from these cancers in that there are currently no
recommended screening options, and, while there are
lifestyle-related factors that affect PC risk such as obesity
[43] and cigarette smoking [44], no single factor has
been identified that can dramatically reduce risk. Given
the current limitations of the science of PC prevention,
methods of early detection are needed.
Interestingly in this study, nearly 1 in 5 PC family
members indicated they were “not at all worried” about
getting PC. This finding could reflect lack of awareness
regarding familial risk, a general belief that worry is un-
productive, illusion of unique invulnerability [45,46] or a
sense of futility in worrying about this deadly disease
based on experience with a family member. Each of
these possible explanations warrants empirical study, as
lack of worry/concern could lead to complacency among
a group of individuals who may benefit greatly from vigi-
lance regarding early warning signs or heightened aware-
ness of developments in screening. Patient education
regarding PC risk and recommendations for surveillance
among those at high risk is needed [34].
Sensitivity and specificity of screening tests are sophis-
ticated, yet critical concepts for patients to understand
prior to undergoing a screening test. The difference
observed in this study between PC family members and
controls with regard to acceptance of false negatives is a
novel finding warranting further study. Greater accept-
ance of personal false negative test results among PC
family members may reflect an experiential bias (relative
to controls) that treatment is only rarely successful in
changing the course of the disease, thus, “missing” the
diagnosis can be viewed with greater acceptance. This
interpretation, if valid, may reflect both cognitive (actual
knowledge-based) and affective (emotional) responses
resulting from experience with the course of PC in their
family member. This same logic would support the
trend-level findings observed regarding greater global
acceptance of missing a diagnosis of PC among PC fam-
ily members as compared to controls.
This research has several strengths including its focus
on cancer of the pancreas, which remains the deadliest
cancer. In addition, this research is one of the few psy-
chosocial studies involving a relatively large sample of
PC family members that also includes a control group.
Finally, the importance and timeliness of the research
cannot be understated; the incidence of PC is continuing
to rise and effective screening methods are the focus of
ongoing translational research. Despite these strengths,
several limitations are important to note including non-independence that was unique to the PC family sample.
Statistical approaches such as GEE can account for non-
independence, but our findings should still be interpreted
with caution. Moreover, PC families with BRCA1/2 and
CDKN2A mutations were not excluded from the study;
these families may have greater familiarity with cancer
screening tests and their attitudes may differ in import-
ant ways from other PC family members. Second, this
was a cross-sectional study assessing behavioral inten-
tions toward hypothetical screening tests; it is inappro-
priate and premature to extrapolate these findings to
future participation in screening tests for pancreatic can-
cer. Nonetheless, the utility of assessing intentions and
acceptability regarding new methods of early cancer de-
tection and prevention prior to their availability has been
demonstrated in other cancers (e.g., spiral CT for early
detection of lung cancer [32] and HPV vaccination for
the prevention of cervical cancer [47]); such research is
critical for the successful development and uptake of new
strategies to detect and prevent cancer. Finally, as one of
the first studies to provide data about receptivity to
screening options for PC, it is limited in scope and not
comprehensive. The assessments of perceived risk and
acceptability of false-negatives/false-positives in this
study avoided numeracy concerns but were compro-
mised by imprecision. Future studies should explore con-
cerns related to sensitivity and specificity of potential
screening tests in greater detail as well as other barriers
to early detection such as cost and availability; whether
screening confers actual improvement in survival for PC
remains to be determined. Addressing each of these
issues in future studies of individuals and families at sig-
nificant risk of pancreatic cancer will facilitate collective
efforts toward the development and implementation of
appropriate and acceptable screening methods targeting
high-risk individuals.
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